Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyAntibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitisPharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteriaPharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisPharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber modelDevelopment and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICDevelopment of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteersPenetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansThe ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi modelA new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesMIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis
P2860
Q24519008-13860937-79B3-4867-84CC-3F06E61292B2Q28344944-6CBF9905-2F35-4B8F-A812-17811316FB77Q33699541-DBE50B6E-C2C5-4457-AA52-836C88FDC35DQ33976236-268703EA-FEDF-4721-B5D2-05BE1986177AQ33976467-512944C3-843C-4C5F-A77F-7F0B0F8B7361Q33980421-82501F85-6DB4-4A21-AB48-7DE2F57CB04BQ34104410-51F6EFD4-21FC-4D1B-817F-9A126C680567Q35117352-7BD6A197-59B7-476D-9BBA-82988E076073Q35123139-9FF99051-AD12-408E-BE16-C2CB2A949D8DQ35125233-CCB23993-18B4-4E7C-93D7-339E713B15F9Q35126112-CD45B6D4-88E8-4921-8289-C07B320FBDE7Q35136125-93C60464-CB2E-45B5-87DC-B31D3293227DQ35139002-11F608D0-E112-4D45-BBB4-E48B2A467E4FQ35637864-1E55C552-F114-4E76-BD81-E9FE77F990E8Q35814771-4DD60921-B103-40D1-83F0-6EB9A49369ABQ35814807-39FF0F99-D69B-4953-A1C5-BA5D5ED8F914Q35897492-060EF577-B31E-42A4-A178-AAE29977DE75Q36047112-E8BBC811-807B-46C1-825D-F8DE69B1AE94Q36562483-B83C1DB7-2680-4B38-B070-C074A5F80AF0Q36880013-30D3BC80-5D1C-405D-A59B-E3B6F102D3E1Q37624733-3DE5E530-5874-4C5D-9AB6-D10C313E2168Q38167345-4DFA64FE-5B20-49B9-883C-0DE4B2F2E2F8Q39477515-D7B92516-B6BE-41B0-9E11-19024BBADD8DQ39557221-6F23A948-84A9-4B24-8A02-97F9A0712372Q39558024-788CB0B2-FB4A-4862-AAD7-B84FDFD3F157Q39559370-B8577720-722E-425B-A6B8-6061ECBF5DF4Q39559375-7450D7C9-903B-409C-8BB7-657EA9EC1D4BQ39650985-5EEE81EB-F757-48D2-95F1-DF5C1E085302Q39781130-62B2206B-C8EF-498B-830E-0B96C0E35B10Q39781591-CC69725C-D530-4303-9698-54AFE0F56046Q39785256-EEFDA84E-E7B0-44D3-A222-AD4CE45681B3
P2860
Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Mathematical examination of du ...... ciprofloxacin, and tobramycin.
@en
type
label
Mathematical examination of du ...... ciprofloxacin, and tobramycin.
@en
prefLabel
Mathematical examination of du ...... ciprofloxacin, and tobramycin.
@en
P2093
P1476
Mathematical examination of du ...... ciprofloxacin, and tobramycin.
@en
P2093
P304
P577
1991-10-01T00:00:00Z